Organizer: Cambridge Centre for Law, Medicine and Life Sciences (LML) in combination with the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the University of Copenhagen
Biologics include some of the most innovative and expensive drugs today. They also raise some of the more complex intellectual property (IP) strategies. Patents provide exclusivity in national markets for the molecules, and trade secrecy shrouds the complex, secret manufacturing processes. Academics, policymakers and industry experts question whether the IP arrangements undermine innovation, efficiency, and competition. The symposium focused on important policy issues for pharmaceutical biologics and competitive biosimilars. In particular, it examined new ideas for innovative partnerships, trade secret disclosure, and evaluation of similarity. We also considered how the legal architecture both encouraged and impeded the development and manufacturing of COVID-19 vaccines. Timo Minssen was one of the event moderators. Hosted by the University of Cambridge, an international hub for legal and scientific expertise, we hope the event will stimulate discussion between legal, economic, business, medical, and scientific experts at a range of career stages. Participants include: Timo Minssen (University of Copenhagen) Prof. Kathy Liddell (University of Cambridge) Prof. Nicholson Price (University of Michigan) Prof. Ariel D. Stern (Harvard Business School) Prof. Jorge Contreras (University of Utah / London School of Economics) Dr Louise Druedahl (University of Copenhagen) Dr Amanda Easey (Penningtons Manches Cooper) Dr Martin Schiestl (Sandoz) Prof. Ken Shadlen (London School of Economics) The 2023 CeBIL Symposium is organised by the Cambridge Centre for Law, Medicine and Life Sciences (LML) in combination with the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the University of Copenhagen. The Symposium is generously supported by the Novo Nordisk Foundation.